I sit down with endocrinologist and diabetes tech expert Dr. David Ahn to unpack the future of tubeless insulin pumps and automated insulin delivery for people with type 1 diabetes. We break down how companies like Omnipod, Tandem (with its tubeless Mobi and 7-day infusion set), Beta Bionics with its reusable mint patch pump, and Medtronic’s upcoming MiniMed Fit are racing to own the next generation of patch pumps. We talk about what Omnipod needs to do with its next-gen system to stay competitive, why 7-day wear and reusable parts matter, and how algorithms—from Loop to iLet—are evolving toward more hands-off, closed-loop insulin delivery. We also dig into big questions around dual-hormone systems using glucagon, how far current CGM technology can really take us, and whether fully closed-loop insulin pump systems without carb counting are actually realistic.
Join the Diabetech Newsletter
Learn about Omnipod 5 (today's sponsor)*
T1D Exchange Registry Sign up (US residents only)
Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Threads
DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.
*10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
